Evidence map›Paper›PMID 24030045›Full record

ArticleTransgenic research2014

Generation of mice with conditional ablation of the Cd40lg gene: new insights on the role of CD40L.

Angélica Horrillo, Tomás Fontela, Elena G Arias-Salgado, Dolores Llobat, Gracia Porras, Matilde S Ayuso, Consuelo González-Manchón

Abstract read
PubMed Publisher
In one paragraph

Article in Transgenic research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. New frontiers for platelet CD154.Experimental hematology & oncology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Angélica HorrilloCIBER de Enfermedades Raras (CIBERER), Madrid, Spain.
Tomás Fontela
Elena G Arias-Salgado
Dolores Llobat
Gracia Porras
Matilde S Ayuso
Consuelo González-Manchón
Centre for Biomedical Network Research on Rare Diseases · ESConsejo Superior de Investigaciones Científicas · ESInstituto de Investigación de Enfermedades Raras · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD40 ligand (CD40L) acts as an immune modulator in activated T cells, and mutations in the extracellular domain are associated to X-linked hyper IgM syndrome. A role for platelet CD40L in mediating thrombotic and inflammatory processes in atherosclerosis has also been reported. Using the Cre/loxP recombination technology we generated four knockout lines of mice with deletion of the Cd40lg gene restricted to the hematopoietic system. Mouse lines with expression of Cre recombinase driven by the Tie2, Vav1, or CD4 promoters showed in vivo ablation of CD40L in leukocytes and platelets. In contrast, in mice with Cre expression driven by the megakaryocyte lineage-restricted Pf4 promoter, abolition of CD40L expression was observed in megakaryocytes cultured in vitro, but not in circulating platelets. Characterization of these animals revealed reduced in vivo thrombogenesis and defective activation of washed CD40L-deficient platelets, suggesting that membrane-bound CD40L is involved in the control of haemostasis acting as a platelet co-activator. In addition, we report the practically absence of CD40L in mouse and human endothelial cells, as well as the detection of an exon 3-deleted CD40L transcript in both platelets and leukocytes of mouse and human origin. Finally, compared with their corresponding littermate floxed controls, Cre+ mice carrying CD40-deficient leukocytes did not exhibit increased IgM levels, and reduction of IgA and IgG levels was statistically significant only in Tie2-Cre+ mice, suggesting that expression of CD40L in an earlier developmental step may be determinant in the regulation of the class switch recombination process.

Indexed as

AnimalsAtherosclerosisBlood PlateletsCD40 LigandGene Expression Regulation, DevelopmentalHumansImmunoglobulin AImmunoglobulin GIntegrasesLeukocytesMegakaryocytesMiceMice, KnockoutRecombinant Fusion ProteinsCD40Ig protein, recombinantCD40 LigandCre recombinaseImmunoglobulin AImmunoglobulin GIntegrasesRecombinant Fusion Proteins

Identifiers

PMID24030045
OpenAlexW2039649979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.